The British Medical Journal (BMJ) today published online a “Rapid Response” written by PBT president and USA-based HIV/AIDS scientist, Dr. Kunal Saha, in regard to the rampant use of anti-malarial drug, Hydroxychloroquine (HCQ), in treatment of COVID-19 patients in India (see below, also available at the link: https://www.bmj.com/content/369/bmj.m1432/rapid-responses). The US Food and Drug Administration (FDA) last week issued an extraordinary “Drug Safety Communication” to warn all medical professionals about the potential dangers that may be associated with the use of HCQ including cardiac failure and death. Major International medical groups including American Heart Association (AHA), American College for Cardiology (ACC) and Canadian Medical Association Journal (CMAJ) have also warned against the use of HCQ in COVID-19 patients. PBT has already filed a PIL in the Supreme Court of India seeking directions for mandatory precautionary measures in COVID-19 treatment centers to prevent serious injury or death of patients receiving the unproven therapy with HCQ. PBT has also sought that “informed consent” must be obtained prior to starting HCQ treatment on COVID-19 patients after full disclosure of the potential adverse effects of this drug. This PIL is expected to come up for hearing via videoconferencing before the Apex Court soon.